Innovative retatrutide, a dual -action drug targeting simultaneously GLP-1 and GIP receptors, is creating considerable interest within the weight loss community. Early clinical trials have demonstrated substantial reductions in overall mass and advancements in health markers for people with excess weight . Experts believe this ground-breaking appr